Docket Number:12A-981008
Inventor:Steve R Roffler, Yu-Lin Leu, Zeljko M Prijovich
IP Status:TW I457127、PCT-US 9,353,140 B2
Abstract:
We developed second-generation camptothecin glucuronide prodrug (BQC-G). The parent drug BQC displayed more cytotoxicity to a panel of cancer cells (IC50 value = 1-2 nM) than camptothecin, 9AC, SN-38 or topotecan but was poorly soluble in water. By contrast, BQC-G was over 4000 times more water soluble, displayed good stability in human plasma and was an excellent substrate for enzymatic hydrolysis by bacterial and human β-glucuronidases. Moreover, BQC-G was about 20-40 times less toxic than BQC, but was as active as BQC after hydrolysis by β-glucuronidase. Importantly, BQC maintained potent cytotoxicity in the presence of human serum albumin (IC50 = 13.3 nM) where BQC-G was preferentially neutralized (IC50 = 1080 nM). BQC-G is a promising candidate for cancer monotherapy and targeted-enzyme based tumor therapies.
Fields of Application:
Cancer therapy, pharmaceuticals
Advantages when compared to the existing technologies:
We previously described the conjugation of 9AC with glucuronic acid via a self-immolative carbamate linker to create a glucuronide derivative named 9-amino-camptothecin-glucuronide (9AC-G, 6). 9AC-G displayed enhanced solubility and remarkable potency against solid human tumor xenografts in mice, further substantiating the utility of β-glucuronidase as a target for prodrug design. However, in common with camptothecin, the presence of human serum albumin (HSA) greatly reduced the anticancer activity of 9AC-G due to strong binding of 9AC to HSA. Development of tumor-selective camptothecin derivatives that are effective in the presence of HSA is therefore highly desirable. To overcome this problem, we created a glucuronide prodrug (BQC-G) of a novel 6-ring CPT derivative BQC that is more active than camptothecin in vitro and displays impressive antitumor activity against P388 leukemia in mice. BQC-G displays properties consistent with its use in targeted cancer therapy and cancer monotherapy. BQC-G was about 4000 times more water soluble than BQC, facilitating formulation in water-based systems. BQC-G was substantially less toxic than BQC in vitro, but was rapidly converted to BQC by β-glucuronidase. BQC-G displayed even less toxicity in the presence of physiological concentrations of human serum albumin, but remained an excellent substrate for β-glucuronidase. Importantly, BQC retained low nM cytotoxicity even in the presence of HSA. These properties, along with the potent in vivo antitumor activity of BQC, suggest that BQC-G is a promising prodrug for the clinical treatment of tumors that display elevated levels of β-glucuronidase due to necrotic release of β-glucuronidase from intracellular stores or due to an inflammatory microenvironment.
Contact Person:Mei-Fang Lee / 886-2-2787-2503 / mflee@gate.sinica.edu.tw
